Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry

Journal of the Neurological Sciences

Volumn 376, Issue , 2017, Pages 84-90

  Trosch, Richard M ^a   Espay, Alberto J ^b   Truong, Daniel ^c   Gil, Ramon ^d   Singer, Carlos ^e   LeWitt, Peter A ^f   Lew, Mark F ^g   Tagliati, Michele ^h   Adler, Charles H ⁱ   Chen, Jack J ^j   Marchese, Dominic ^k   Comella, Cynthia L ^l  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Parkinson's and Movement Disorder Institute   (United States)

^d Center of SW Florida (d/b/a Charlotte Neurological Services)   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

^j MARSHALL B KETCHUM UNIVERSITY   (United States)

^k IPSEN   (France)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

AbobotulinumtoxinA; Botulinum toxin; Cervical dystonia; Cervical pain; Disability; Torticollis

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; MUSCLE RELAXANT AGENT;

ADULT; ARTICLE; ASTHENIA; BLURRED VISION; CERVICAL DYSTONIA; CLINICAL PRACTICE; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; HUMAN; LEVATOR SCAPULAE MUSCLE; LONGISSIMUS MUSCLE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NECK PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; RATING SCALE; RHINORRHEA; TORONTO WESTERN SPASMODIC TORTICOLLIS RATING SCALE; TORTICOLLIS; TRAPEZIUS MUSCLE; TREATMENT RESPONSE; UNITED STATES; CLINICAL TRIAL; COMPLICATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; REGISTER; TREATMENT OUTCOME;

BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NECK PAIN; NEUROMUSCULAR AGENTS; REGISTRIES; TORTICOLLIS; TREATMENT OUTCOME; UNITED STATES;

EID: 85014854661     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2017.02.042     Document Type: Article

References (15)

1. [1] Jinnah, H.A., Berardelli, A., Comella, C., Defazio, G., Delong, M.R., Factor, S., Galpern, W.R., Hallett, M., Ludlow, C.L., Perlmutter, J.S., Rosen, A.R., The focal dystonias: current views and challenges for future research. Mov. Disord. 28 (2013), 926–943.
2. [2] Benecke, R., Frei, K., Comella, C., Treatment of cervical dystonia. Truong, D., Dressler, D., Hallett, M., (eds.) Manual of Botulinum Toxin Therapy, 2009, Cambridge Univerisity Press, Cambridge, 29–42.
3. [3] Defazio, G., Jankovic, J., Giel, J.L., Papapetropoulos, S., Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet. Mov. (N. Y.), 3, 2013 pii: tre-03-193-4374-2.
4. [4] Van Zandijcke, M., Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol. Belg. 95 (1995), 210–215.
5. [5] Marras, C., Van den Eeden, S.K., Fross, R.D., Benedict-Albers, K.S., Klingman, J., Leimpeter, A.D., Nelson, L.M., Risch, N., Karter, A.J., Bernstein, A.L., Tanner, C.M., Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology 69 (2007), 676–680.
6. [6] Simpson, D.M., Blitzer, A., Brashear, A., Comella, C., Dubinsky, R., Hallett, M., Jankovic, J., Karp, B., Ludlow, C.L., Miyasaki, J.M., Naumann, M., So, Y., Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70 (2008), 1699–1706.
7. [7] Albanese, A., Asmus, F., Bhatia, K.P., Elia, A.E., Elibol, B., Filippini, G., Gasser, T., Krauss, J.K., Nardocci, N., Newton, A., Valls-Sole, J., EFNS guidelines on diagnosis and treatment of primary dystonias. Eur. J. Neurol. 18 (2011), 5–18.
8. [8] Comella, C.L., Thompson, P.D., Treatment of cervical dystonia with botulinum toxins. Eur. J. Neurol. 13:Suppl. 1 (2006), 16–20.
9. [9] Swope, D., Barbano, R., Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol. Clin. 26:Suppl. 1 (2008), 54–65.
10. [10] DYSPORT® for Injection (AbobotulinumtoxinA) [Prescribing Information]. 2016, Ipsen Biopharmaceuticals, Inc, Basking Ridge, NJ.
11. [11] Truong, D., Brodsky, M., Lew, M., Brashear, A., Jankovic, J., Molho, E., Orlova, O., Timerbaeva, S., Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat. Disord. 16 (2010), 316–323.
12. [12] Truong, D., Duane, D.D., Jankovic, J., Singer, C., Seeberger, L.C., Comella, C.L., Lew, M.F., Rodnitzky, R.L., Danisi, F.O., Sutton, J.P., Charles, P.D., Hauser, R.A., Sheean, G.L., Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov. Disord. 20 (2005), 783–791.
13. [13] Jankovic, J., Adler, C.H., Charles, D., Comella, C., Stacy, M., Schwartz, M., Adams, A.M., Brin, M.F., Primary results from the Cervical Dystonia Patient Registry for observation of onabotulinumtoxinA efficacy (CD PROBE). J. Neurol. Sci. 349 (2015), 84–93.
14. [14] Jankovic, J., Adler, C.H., Charles, P.D., Comella, C., Stacy, M., Schwartz, M., Sutch, S.M., Brin, M.F., Papapetropoulos, S., Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol., 11, 2011, 140.
15. [15] Fernandez, H.H., Pagan, F., Danisi, F., Greeley, D., Jankovic, J., Verma, A., Sethi, K., Pappert, E.J., Prospective study evaluating IncobotulinumtoxinA for cervical dystonia or blepharospasm: interim results from the first 145 subjects with cervical dystonia. Tremor Other Hyperkinet. Mov. (N. Y.), 3, 2013.